ABSTRACT:
Despite the clinical success of modern antihyperglycemic agents, current diabetes therapeutics face significant limitations and challenges that hinder optimal disease management in 2026. While SGLT2 inhibitors and GLP-1 receptor agonists have redefined care by offering cardiorenal protection, their widespread adoption is restricted by high costs, gastrointestinal intolerance, and rare but serious risks like euglycemic ketoacidosis. Furthermore, the traditional "treat-to-failure" model often leads to clinical inertia, where treatment intensification is delayed despite suboptimal glycemic control. Patient-level challenges, including polypharmacy, the psychological burden of injectable therapies, and the complexity of automated insulin delivery (AID) systems, contribute to persistent gaps in adherence. Additionally, most current therapies address symptoms rather than the underlying beta-cell decline, leaving a critical unmet need for regenerative or disease-modifying treatments. This abstract highlights the urgent necessity for more accessible, simplified, and physiologically targeted interventions to overcome these systemic and biological barriers.